Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2003 Mar;111(5):595-7.
doi: 10.1172/JCI18044.

Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy

Salem Chouaib  1
Affiliations
Comment

Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy

Salem Chouaib. J Clin Invest. 2003 Mar.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998;4:321. - PMC - PubMed
    1. Molldrem JJ, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 2003;111:639–647. doi:10.1172/JCI200316398. - PMC - PubMed
    1. Molldrem JJ. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogeous leukemia. Nat. Med. 2000;6:1018–1023. - PubMed
    1. Echchakir H, et al. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. U. S. A. 2002;99:9358–9363. - PMC - PubMed
    1. Dutoit V, et al. Multiepitope CD(8+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 2002;110:1813–1822. doi:10.1172/JCI200216428. - PMC - PubMed

Substances